Cargando…

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

BACKGROUND: Patients with advanced colorectal cancer (CRC) have a poor prognosis. Combinations of immunotherapies and anti-angiogenic agents are currently being evaluated in clinical trials. In this study, the multikinase inhibitor regorafenib (REG) was combined with an anti-programmed cell death pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doleschel, Dennis, Hoff, Sabine, Koletnik, Susanne, Rix, Anne, Zopf, Dieter, Kiessling, Fabian, Lederle, Wiltrud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436536/ https://www.ncbi.nlm.nih.gov/pubmed/34517894 http://dx.doi.org/10.1186/s13046-021-02043-0

Ejemplares similares

Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid
por: Mueller-Diesing, Flurin, et al.
Publicado: (2023)

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer()()
por: Fiegle, E, et al.
Publicado: (2019)

Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects
por: Lederle, Wiltrud, et al.
Publicado: (2011)

Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response
por: Zafarnia, Sara, et al.
Publicado: (2017)

Erythropoietin Improves the Accumulation and Therapeutic Effects of Carboplatin by Enhancing Tumor Vascularization and Perfusion
por: Doleschel, Dennis, et al.
Publicado: (2015)

Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and (18)F-FDG-PET/CT
por: Gross, Jasmin, et al.
Publicado: (2021)

Hybrid µCT-FMT imaging and image analysis
por: Gremse, Felix, et al.
Publicado: (2015)

Non-invasive Imaging and Modeling of Liver Regeneration After Partial Hepatectomy
por: Zafarnia, Sara, et al.
Publicado: (2019)

Development of a Systematic Review Protocol and a Scoping Review of Ultrasound-Induced Immune Effects in Peripheral Tumors
por: Rix, Anne, et al.
Publicado: (2021)

Bio-degradable highly fluorescent conjugated polymer nanoparticles for bio-medical imaging applications
por: Repenko, Tatjana, et al.
Publicado: (2017)

Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease
por: Woitok, Marius Maximilian, et al.
Publicado: (2020)

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery
por: Paefgen, Vera, et al.
Publicado: (2015)

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
por: Huynh, Hung, et al.
Publicado: (2015)

Targeted immunotherapy for hair regrowth and regeneration
por: Toh, En Qi, et al.
Publicado: (2023)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Absorption Reconstruction Improves Biodistribution Assessment of Fluorescent Nanoprobes Using Hybrid Fluorescence-mediated Tomography
por: Gremse, Felix, et al.
Publicado: (2014)

A proof-of-concept pipeline to guide evaluation of tumor tissue perfusion by dynamic contrast-agent imaging: Direct simulation and inverse tracer-kinetic procedures
por: Vignon-Clementel, Irene E., et al.
Publicado: (2023)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
por: Shigeta, Kohei, et al.
Publicado: (2020)

Regorafenib prevents the development of emphysema in a murine elastase model
por: Oh, Kwangseok, et al.
Publicado: (2023)

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
por: Daudigeos-Dubus, Estelle, et al.
Publicado: (2015)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Influence of Sonication on Bacterial Regrowth from Antibiotic Loaded PMMA Scaffolds - An In-vitro Study
por: Clauss, Martin, et al.
Publicado: (2017)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rnhgi356ebucap620j8sfbreh2